2023
Caprini risk assessment model combined with D-dimer to predict the occurrence of deep vein thrombosis and guide intervention after laparoscopic radical resection of colorectal cancer
Zhang W, Sun R, Hu X, Chen Z, Lai C. Caprini risk assessment model combined with D-dimer to predict the occurrence of deep vein thrombosis and guide intervention after laparoscopic radical resection of colorectal cancer. World Journal Of Surgical Oncology 2023, 21: 299. PMID: 37735407, PMCID: PMC10512522, DOI: 10.1186/s12957-023-03183-7.Peer-Reviewed Original ResearchConceptsCaprini risk assessment modelLow-molecular-weight heparinLaparoscopic radical resection of colorectal cancerResection of colorectal cancerRadical resection of colorectal cancerLaparoscopic radical resectionLMWH groupD-dimerDeep vein thrombosisCut-off valueVein thrombosisROC curveColorectal cancerIPC groupClinical data of patientsLow incidence of thrombosisOccurrence of deep vein thrombosisAccurate risk stratificationDecision curve analysisData of patientsColorectal cancer patientsIncidence of thrombosisIncidence of DVTMolecular weight heparinArea under the ROC curve
2022
Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer
Li Y, Gan Y, Liu J, Li J, Zhou Z, Tian R, Sun R, Liu J, Xiao Q, Li Y, Lu P, Peng Y, Peng Y, Shu G, Yin G. Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancer. Signal Transduction And Targeted Therapy 2022, 7: 87. PMID: 35351858, PMCID: PMC8964798, DOI: 10.1038/s41392-022-00902-6.Peer-Reviewed Original ResearchConceptsOxaliplatin resistanceColorectal cancerTumor growthMEIS1 expressionCell sensitivity to oxaliplatinPreventing DNA damage repairCombination of oxaliplatinSurvival of CRC patientsTreatment of colorectal cancerSensitivity to oxaliplatinEZH2 inhibitor GSK126Suppressed tumor growthReverse oxaliplatin resistanceFrontline treatmentAcquired resistanceCRC patientsInhibitor GSK126OxaliplatinFEN1 expressionTherapeutic strategiesDNA damage repairELFN1-AS1Cell survivalMeis1Patients